Clinical Trials in Los Angeles

Showing 7641-7660 of 12,794 trials

A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression

NCT01536743

The purpose of this study is to obtain an estimate of the biochemical response rate as determined by CA125 response using the Gynecologic Cancer Intergroup (GCIG) response criteria of PD0332991 in patients with recurrent ovarian epithelial carcinoma. CA125 response is defined as ≥ 50% decrease from the baseline CA125 level and confirmed ≥ 21 days after initial evaluation (baseline is defined as the higher value of 2 pre-treatment CA125 assessments).

Ovarian Epithelial Carcinoma

Jonsson Comprehensive Cancer Center26 participantsStarted Dec 2011

Los Angeles, California, United States

COMPLETEDPhase 3< 1 mile

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT02277769

This is a randomized, double-blind, placebo-controlled, parallel-group study to confirm the efficacy and safety of Dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis (AD).

Dermatitis, Atopic

Regeneron Pharmaceuticals708 participantsStarted Nov 2014

Anniston, Alabama, United States • Birmingham, Alabama, United States • Phoenix, Arizona, United States +90 more locations

A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Find Trials by Condition in Los Angeles

Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

Immunotherapy Study for Surgically Resected Pancreatic Cancer

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

Vaccine Study for Surgically Resected Pancreatic Cancer

Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy

CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

Non-invasive Buttock Lifting Induced by Magnetic Device - Multicentric Study

A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea

Dose-Ranging Study of the Bimatoprost Ocular Insert

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age

Comparing the ADR With Air Insufflation, Water Immersion and Water Exchange During Two-endoscopist Colonoscopy

VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease

INdividualized ITI Based on Fviii(ATE) Protection by VWF

Transvenous Lead Removal Post-Market Clinical Study

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Pharmacokinetics of Anti-epileptic Drugs in Obese Children